A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients
Status:
Recruiting
Trial end date:
2024-04-08
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the safety and tolerability of subcutaneous (SC) blinatumomab for
treatment of Acute Lymphoblastic Leukemia (ALL) and to determine the maximum tolerated dose
(MTD), and recommended phase 2 dose (RP2D) of SC administered blinatumomab.